Prosecution Insights
Last updated: April 19, 2026

Examiner: AFREMOVA, VERA

Tech Center 1600 • Art Units: 1653 1657

This examiner grants 51% of resolved cases

Performance Statistics

50.8%
Allow Rate
-9.2% vs TC avg
927
Total Applications
+29.4%
Interview Lift
1340
Avg Prosecution Days
Based on 862 resolved cases, 2023–2026

Rejection Statute Breakdown

8.9%
§101 Eligibility
23.5%
§102 Novelty
37.3%
§103 Obviousness
23.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16604138 ENGINEERED COMMENSAL BACTERIA AND METHODS OF USE Non-Final OA The Regents of the University of California
17955413 PREBIOTIC FORMULATIONS Final Rejection Ohio State Innovation Foundation
17172528 CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION Final Rejection GENENTECH, INC.
17605374 GENE TARGETS FOR NITROGEN FIXATION TARGETING FOR IMPROVING PLANT TRAITS Non-Final OA Pivot Bio, Inc.
18047384 METHOD FOR ESTIMATING CULTURE STATE, INFORMATION PROCESSING DEVICE, AND PROGRAM Final Rejection FUJIFILM Corporation
18064511 COLORIMETRIC ASSAY FOR HIGH THROUGHPUT, FACILE AND RAPID ANTIMICROBIAL SUSCEPTIBILITIES TESTING Final Rejection Georgia Tech Research Corporation
17608274 FEED COMPOSITIONS CONTAINING BETAINE SALTS Non-Final OA Evonik Operations GmbH
14898679 METHOD FOR STORING EXCESS ENERGY Non-Final OA Evonik Operations GmbH
17920893 MICROVESICLE ISOLATION METHOD AND MICROVESICLE ISOLATION Final Rejection Korea University Research and Business Foundation
18022201 Label-free, real-time, whole-cell response monitoring with liquid Raman spectroscopy Final Rejection The Board of Trustees of the Leland Stanford Junior University
17698257 AGENT FOR PROMOTING COLLAGEN PRODUCTION, MEDICAMENT, COSMETIC, AND METHOD FOR MANUFACTURING AGENT FOR PROMOTING COLLAGEN PRODUCTION Final Rejection Murata Manufacturing Co., Ltd.
19067759 NOVEL METHOD TO ALTER THE PROTEOME OF A DISEASED HEART BY INJECTION OF ECM PARTICLES PRODUCED FROM DECELLULARIZED 3D MICROTISSUES OF HUMAN MESENCHYMAL STEM CELLS Non-Final OA XM Therapeutics, Inc.
17919142 METHODS AND SYSTEMS OF ENHANCING OPTICAL SIGNALS OF EXTRACELLULAR VESICLES Final Rejection The General Hospital Corporation
19028716 STRAIN OF ENTEROCOCCUS FAECALIS, COMPOSITE BACTERIAL AGENT AND APPLICATIONS THEREOF Final Rejection HEALTH AND HAPPINESS (H&H) HONG KONG LIMITED
18629273 DIAGNOSIS AND TREATMENT OF FUSARIOSIS AND SCEDOSPORIOSIS Final Rejection The Brigham and Women's Hospital, Inc.
18985909 METHOD FOR ENHANCING IMMUNE SYSTEM FUNCTIONS IN A SUBJECT Final Rejection Macularity, Inc.
17801002 METHODS FOR REHABILITATING HEART FAILURE USING GENE THERAPY Non-Final OA UNIVERSITY OF UTAH RESEARCH FOUNDATION
18861561 PROBIOTICS FOR THE PREVENTION OR TREATMENT OF VIRAL RESPIRATORY INFECTIONS Non-Final OA SUPERBIOTICS SRL
17736430 METHOD FOR PRODUCING COLLAGEN PEPTIDES FROM BONES, AND PRODUCED COLLAGEN PEPTIDES Non-Final OA GELITA AG
15474723 PROBIOTIC COMPOSITIONS AND METHODS Final Rejection CORNELL UNIVERSITY
17755955 COMPOSITIONS, KITS AND METHODS FOR STORAGE OF BLOOD PRODUCTS AND METHODS OF USE THEREOF Final Rejection Rutgers, The State University of New Jersey
16866154 POLYHYDROXYALKANOATE PRODUCTION METHOD Final Rejection Newlight Technologies, Inc.
17760615 SEAWEED-BASED COMPOSITION Final Rejection Cargill, incorporated
18591819 HOST-BIOME INTERACTIONS Non-Final OA Emulate, Inc.
18532577 MANIPULATION OF TRYPTAMINE METABOLISM Final Rejection Seres Therapeutics, Inc.
17642328 METHODS FOR REDUCTION OF BITTERNESS IN CANNABINOIDS USING MYCELIAL MATERIALS Non-Final OA MYCOTECHNOLOGY, INC.
17640456 Method For Capturing And Purification Of Biologics Final Rejection Amicus Therapeutics, Inc.
18283424 SPIRULINA-BASED COMPOSITION AND USES THEREOF FOR REINFORCING IMMUNITY Non-Final OA Axeen Pharma
18260421 USE OF DEOXYRIBONUCLEASE I IN THE TREATMENT OF ENDOMETRIOSIS IN PATIENTS WITH AN EPIGENETIC SIGNATURE OF ENDOMETRIOSIS ON CELL-FREE DNA Non-Final OA Endolife
18252560 AIR MONITORING SYSTEMS AND METHODS Non-Final OA U-EARTH BIOTECH LTD

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month